Vivoryon Therapeutics N.V. · EURONEXT:VVY

Vivoryon Therapeutics — FY2020 Earnings Presentation

22 slides from Vivoryon Therapeutics's earnings presentation, Apr 30, 2021

  1. Slide 1: 2020 Full Year Results & Outlook 2021

    2020 FULL YEAR RESULTS & OUTLOOK 2021 Halle (Saale)/Munich, April 30, 2021 | Vivoryon Therapeutics N.V.

  2. Slide 2: Important Notice and Disclaimer

    IMPORTANT NOTICE AND DISCLAIMER This Presentation has been prepared and issued by Vivoryon Therapeutics (the “Company”) and has not been independently verified by any third party. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on,

  3. Slide 3: Welcome to Vivoryon Therapeutics

    WELCOME TO VIVORYON THERAPEUTICS - on the call today - Dr. Ulrich Dauer Florian Schmid Dr. Michael Schaeffer Chief Executive Officer Chief Financial Officer Chief Business Officer © Vivoryon Therapeutics N.V. FY 2020 – April 30, 2021 3

  4. Slide 4: Agenda

    01 HIGHLIGHTS IN 2020 02 R&D UPDATE AND OUTLOOK AGENDA 03 CORPORATE UPDATE AND OUTLOOK 04 FINANCIALS 2020 05 CLOSING REMARKS 06 Q&A © Vivoryon Therapeutics N.V. FY 2020 – April 30, 2021

  5. Slide 5: Highlights in 2020

    01 HIGHLIGHTS IN 2020

  6. Slide 6: Highlights 2020

    HIGHLIGHTS 2020 Highlights § Start of development program for meprin protease inhibitors with intended therapeutic use in fibrosis and cancer § Enrollment of First Patient in VIVIAD, European Phase 2b Alzheimer’s Disease Study with Varoglutamstat § Receive of FDA’s IND approval for varoglutamstat‘s

  7. Slide 7: R&D Update and Outlook

    02 R&D UPDATE AND OUTLOOK

  8. Slide 8: Substantial Pipeline Progress

    SUBSTANTIAL PIPELINE PROGRESS © Vivoryon Therapeutics N.V. FY 2020 – April 30, 2021 8

  9. Slide 9: Varoglutamstat (PQ912) in Clinical Phase 2

    VAROGLUTAMSTAT (PQ912) IN CLINICAL PHASE 2 A Phase 2b Multicentre, Randomized, A Phase 2a Randomized Double-Blind Double-blind, Placebo-controlled, Placebo-controlled Trial to Evaluate the Parallel Group Dose Finding, Safety, Efficacy and Safety of Varoglutamstat Targeting N3pG: Tolerability and Eff

  10. Slide 10: QPCTL Inhibitors in Oncology: Dual MoA

    QPCTL INHIBITORS IN ONCOLOGY: DUAL MoA § Targeting the CD47-SIRPa innate immune system § First-in-class approach to destabilize and deactivate checkpoint. First-in-class small molecule approach, to the tumorigenic and pro-inflammatory chemokine boost anti tumor antibody therapies CCL2. §. § Extended

  11. Slide 11: Meprin: A Novel Fibrosis Target

    MEPRIN: A NOVEL FIBROSIS TARGET § Protease critical for collagen re-modelling and for the activation of inflammatory cytokines (IL-1, IL6…) § Target indications: AKI, CKD, Fibrosis and Cancer § Animal proof-of-concept in AKI model § Portfolio of nanomolar inhibitors selective for Meprin a and b or b

  12. Slide 12: Corporate Update and Outlook

    03 CORPORATE UPDATE AND OUTLOOK

  13. Slide 13: Conversion of Vivoryon into an N.V. Successfully Completed

    CONVERSION OF VIVORYON INTO AN N.V. SUCCESSFULLY COMPLETED N.V. Rationale for the conversion of Vivoryon’s legal form: § Increasing competitiveness in - Fulfillment of capital market requirements AG - Expansion of strategic options - Exploitation of favorable market conditions - Attraction of intern

  14. Slide 14: Shareholders and Stock

    SHAREHOLDERS AND STOCK Shareholder structure1 Stock Share Price ISIN: NL00150002Q7 WKN: A2QJV6 Ticker symbol: VVY Types of shares: Bearer shares Number of shares 19,975,482 Euronext Amsterdam Stock exchange: XETRA, Frankfurt Liquidity provider: Kempen & Co. Listing agent: Kempen & Co. First trading

  15. Slide 15: Financials 2020

    04 FINANCIALS 2020

  16. Slide 16: Key Financial Highlights (P&L): According to IFRS

    KEY FINANCIAL HIGHLIGHTS (P&L): ACCORDING TO IFRS IN €k 2020 2019 % Research and development expenses (13,210) (4,789) 175.8 General and administrative expenses (2,807) (3,062) (8.3) Other operating income 6 59 (89,8) Operating loss (16,510) (7,823) 105.5 Finance income 105 0 Finance expenses (604)

  17. Slide 17: Key Financial Figures (According to IFRS)

    KEY FINANCIAL FIGURES (ACCORDING TO IFRS) In €k Dec 31, 2020 Dec 31, 2019 Earnings, Financial and Net Assets Position Operating loss (16,011) (7,792) Finance result (499) (31) Net loss for the period (16,510) (7,823) Total equity 26,221 42,665 Equity ratio (end of the year) (in %) 88.1% 93.0 % Balan

  18. Slide 18: Closing Remarks

    05 CLOSING REMARKS

  19. Slide 19: Financial Calendar 2021

    FINANCIAL CALENDAR 2021 June 01, 2021 Interim Management Statement Q1 2021 June 28, 2021 Annual General Meeting 2021 September 21, 2021 Interim Report, Half Year Results 2021 November 23, 2021 Interim Management Statement Q3 2021 © Vivoryon Therapeutics N.V. FY 2020 – April 30, 2021 Please note: Sub

  20. Slide 20: Q&A

    06 Q&A

  21. Slide 21: www.vivoryon.com

    www.vivoryon.com Halle (Saale) Munich Weinbergweg 22 Franz-Josef-Delonge-Str. 5 06120 Halle (Saale) 81249 München Germany Germany [email protected] +49 (0)345 555 99 00

  22. Slide 22: Appendix

    APPENDIX

Vivoryon Therapeutics — FY2020 Earnings Presentation on 6ix